FITC anti-mouse CD3 Antibody

Pricing & Availability
Clone
17A2 (See other available formats)
Regulatory Status
RUO
Other Names
T cell antigen receptor complex, T3
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
17A2
C57BL/6 splenocytes stained with 17A2 FITC and 145-2C11 PE
  • 17A2
    C57BL/6 splenocytes stained with 17A2 FITC and 145-2C11 PE
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100203 50 µg 29€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100204 500 µg 115€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
γδTCR-positive T-T hybridoma D1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.

Application References

(PubMed link indicates BioLegend citation)
  1. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  2. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  2. Zhang H, et al. 2021. Front Immunol. 12:644520. PubMed
  3. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  4. Lee JH, et al. 2022. EBioMedicine. 77:103903. PubMed
  5. Zhu Y, et al. 2022. Nat Commun. 13:4282. PubMed
  6. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  7. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  8. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  9. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  10. Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed
  11. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  12. Zaman R, et al. 2021. Immunity. :. PubMed
  13. Gawish R, et al. 2022. Elife. 11:. PubMed
  14. Qiao Y, et al. 2021. Oncoimmunology. 10:1947569. PubMed
  15. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  16. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  17. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  18. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  19. Ford K, et al. 2020. Cancer Res. 80:1846. PubMed
  20. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  21. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  22. Tang L, et al. 2021. Oncol Lett. 22:605. PubMed
  23. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  24. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  25. Miller CM, et al. 2020. J Virol. 94:00:00. PubMed
  26. Boyd DF, et al. 2020. Nature. 587:466. PubMed
  27. Wu X, et al. 2012. Biochem Pharmacol. 84:1164. PubMed
  28. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  29. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  30. Choi YY, et al. 2021. Cell Death Dis. 12:826. PubMed
  31. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  32. Zhang S, et al. 2022. Acta Pharm Sin B. 12:3124. PubMed
  33. Steubing RD, et al. 2022. Brain Behav Immun Health. 24:100493. PubMed
  34. Mei S, et al. 2022. Front Immunol. 13:911164. PubMed
  35. Lu H, et al. 2021. Autophagy. 17:2511. PubMed
  36. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  37. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  38. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  39. Chou YJ, et al. 2020. Sci Rep. 10:8422. PubMed
  40. Bromley SK, et al. 2020. Cell Reports. 32(9):108085. PubMed
  41. Bao H, et al. 2020. Mol Med Rep. 4.675. PubMed
  42. Diao L, et al. 2022. iScience. 25:105511. PubMed
  43. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  44. Huang Y, et al. 2021. Radiother Oncol. 162:34. PubMed
  45. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  46. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  47. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  48. Oliva Chávez AS, et al. 2021. Nat Commun. 12:3696. PubMed
  49. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  50. Sun CC, et al. 2020. Genome Med. 0.553472222. PubMed
  51. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  52. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  53. Dolgova EV, et al. 2022. Int J Mol Sci. 23:. PubMed
  54. Mostafavi H, et al. 2022. PLoS Pathog. 18:e1010185. PubMed
  55. Sala D, et al. 2022. Mol Ther Methods Clin Dev. 25:170. PubMed
  56. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  57. Davis FM, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2353. PubMed
  58. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  59. Lesmeister M, et al. 2005. Reprod Biol Endocrinol. 29:74. PubMed
  60. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  61. Deng P, et al. 2022. Cells. 11:. PubMed
  62. Li Y, et al. 2022. Clin Transl Immunology. 11:e1362. PubMed
  63. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  64. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  65. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  66. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  67. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  68. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  69. White C, et al. 2014. J Immunol. 193:5933. PubMed
  70. Chen Y, et al. 2012. PLoS One. 7:e47190. PubMed
  71. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  72. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  73. Geng T, et al. 2022. Methods Mol Biol. 2585:71. PubMed
  74. Solanki A, et al. 2018. Development. 145. PubMed
  75. Shields BD, et al. 2019. Cancer Res. 79:1113. PubMed
  76. Lee M, et al. 2014. PLoS One. 9:112666. PubMed
  77. Mingozzi F, et al. 2016. EMBO Mol Med. 8: 1039 - 1051. PubMed
  78. Carr RM, et al. 2021. Nat Commun. 12:2901. PubMed
  79. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  80. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  81. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  82. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  83. Kimball AS et al. 2019. Immunity. 51(2):258-271 . PubMed
  84. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  85. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  86. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  87. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  88. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  89. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  90. Wang X, et al. 2018. Mol Med Rep. 17:1660. PubMed
  91. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  92. Comazzetto S et al. 2018. Cell stem cell. 24(3):477-486 . PubMed
  93. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  94. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  95. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  96. Omori S, et al. 2021. Cell Reports. 34(6):108734. PubMed
  97. Ding Y, et al. 2022. Cell Death Dis. 13:996. PubMed
  98. Tang X, et al. 2022. Cell Rep. 41:111673. PubMed
  99. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  100. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  101. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  102. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  103. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  104. Koren E, et al. 2022. Nat Commun. 13:4628. PubMed
  105. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  106. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  107. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  108. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  109. Sreekumar PG, et al. 2018. J Control Release. 283:94. PubMed
  110. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  111. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  112. Xu X, et al. 2018. Cell. 175:1336. PubMed
  113. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  114. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  115. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  116. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  117. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  118. Akhter N, et al. 2016. J Biol Chem. 291: 23672 - 23680. PubMed
  119. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  120. Markey K, et al. 2014. J Immunol. 192:5426. PubMed
  121. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  122. França TT, et al. 2021. JCI Insight. 6:. PubMed
  123. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
  124. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  125. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  126. Moon HG et al. 2018. Immunity. 49(2):275-287 . PubMed
  127. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  128. Du J, et al. 2012. Stem Cells. 30:1447. PubMed
  129. Weinheimer-Haus E, et al. 2014. PLoS One. 9:91355. PubMed
  130. Zheng L, et al. 2020. Front Oncol. 10:531131. PubMed
  131. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  132. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  133. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  134. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  135. Port JR, et al. 2020. J Virol. 94:. PubMed
  136. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  137. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  138. Choi EW, et al. 2020. Sci Rep. 10:12001. PubMed
  139. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  140. Cohen M et al. 2018. Cell. 175(4):1031-1044 . PubMed
  141. Ma W, et al. 2017. Cell Death & Disease. 10.1038/cddis.2017.47. PubMed
  142. Alsina-Sanchis E, et al. 2020. Mol Cancer Res. . PubMed
  143. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  144. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
  145. Xiao Y, et al. 2022. Nat Commun. 13:758. PubMed
  146. Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed
  147. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  148. Yang Z, et al. 2021. Nat Commun. 12:4852. PubMed
  149. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  150. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  151. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  152. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
  153. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  154. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  155. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  156. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  157. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  158. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  159. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  160. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  161. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  162. Scally S, et al. 2017. Nat Commun. . 10.1038/s41467-017-01924-3. PubMed
  163. Wang Z, et al. 2021. Acta Pharm Sin B. 694:11. PubMed
  164. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  165. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  166. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  167. Cabrera-Perez J, et al. 2016. J Immunol. 197: 1692 - 1698. PubMed
  168. Kang J, Lee J, Chang J 2016. PLoS One. 11: 0157015. PubMed
  169. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  170. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  171. Smith-Díaz CC, et al. 2021. Front Oncol. 11:709543. PubMed
  172. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  173. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  174. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
  175. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  176. Li M, et al. 2021. Br J Pharmacol. 178:2617. PubMed
  177. Yang YS, et al. 2022. Nat Commun. 13:6175. PubMed
  178. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  179. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  180. Nam J, et al. 2021. Adv Ther (Weinh). 4:. PubMed
  181. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  182. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  183. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  184. van den Berk P, et al. 2020. Cell Rep. 33:108533. PubMed
  185. Baumann D, et al. 2020. Nat Commun. 1.969444444. PubMed
  186. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
  187. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  188. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  189. Campolo M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  190. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  191. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  192. Fujimoto M, et al. 2022. Nat Commun. 13:5408. PubMed
  193. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  194. Ravindran Menon D, et al. 2021. Pharmaceuticals (Basel). 14:. PubMed
  195. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  196. Aulova KS, et al. 2022. Molecules. 27:. PubMed
  197. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  198. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  199. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  200. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  201. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  202. Tao Z, et al. 2022. Cells. 11:. PubMed
  203. Tang T, et al. 2022. J Immunother Cancer. 10:. PubMed
  204. Zhou Y, et al. 2022. Theranostics. 12:5488. PubMed
  205. Chen LH, et al. 2021. Sci Rep. 11:19478. PubMed
  206. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  207. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  208. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  209. Pan X, et al. 2019. BMC Complement Altern Med. 19:163. PubMed
  210. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  211. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  212. Zukauskas A, et al. 2018. mSphere. 3:e00303. PubMed
  213. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  214. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  215. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  216. Mincham KT, et al. 2021. Front Immunol. 11:601494. PubMed
  217. Zheng Y, et al. 2022. Transl Res. :. PubMed
  218. Gawish R, et al. 2022. Elife. 11:. PubMed
  219. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  220. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  221. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  222. Tur J, et al. 2020. Cell Reports. 32(8):108079. PubMed
  223. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  224. Goldberg EL, et al. 2021. Cell Metabolism. :. PubMed
  225. Sun Q, et al. 2022. J Inflamm Res. 15:5827. PubMed
  226. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  227. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  228. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  229. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  230. Zhang J, et al. 2021. Stem Cell Res Ther. 12:579. PubMed
  231. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  232. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  233. Zheng QY, et al. 2020. FASEB J. 34:10590. PubMed
  234. Martínez-Vicente P, et al. 2019. PLoS Pathog. 15:e1007658. PubMed
  235. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  236. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  237. Li J, et al. 2021. eLife. 10:00. PubMed
  238. Trivedi S, et al. 2020. Elife. 9:00. PubMed
  239. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  240. Fan X, et al. 2014. PLoS One. 9:107638. PubMed
RRID
AB_312660 (BioLegend Cat. No. 100203)
AB_312661 (BioLegend Cat. No. 100204)

Antigen Details

Structure
Ig superfamily, CD3/TCR, 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor
Peptide antigen/MHC-complex
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12502 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD3 Reagents Request Custom Conjugation
Description Clone Applications
FITC anti-mouse CD3 17A2 FC
PE anti-mouse CD3 17A2 FC
Purified anti-mouse CD3 17A2 FC, IHC-F, IP, ICC
Alexa Fluor® 647 anti-mouse CD3 17A2 FC, IHC-F, 3D IHC
Alexa Fluor® 488 anti-mouse CD3 17A2 FC, IHC-F, 3D IHC
Pacific Blue™ anti-mouse CD3 17A2 FC
Alexa Fluor® 700 anti-mouse CD3 17A2 FC
PerCP/Cyanine5.5 anti-mouse CD3 17A2 FC
PE/Cyanine7 anti-mouse CD3 17A2 FC
APC/Cyanine7 anti-mouse CD3 17A2 FC
Brilliant Violet 421™ anti-mouse CD3 17A2 FC, ICC
Brilliant Violet 570™ anti-mouse CD3 17A2 FC
Brilliant Violet 650™ anti-mouse CD3 17A2 FC
Brilliant Violet 785™ anti-mouse CD3 17A2 FC
Brilliant Violet 510™ anti-mouse CD3 17A2 FC
APC anti-mouse CD3 17A2 FC
Ultra-LEAF™ Purified anti-mouse CD3 17A2 FC, IHC-F, IP, ICC
Brilliant Violet 605™ anti-mouse CD3 17A2 FC
Alexa Fluor® 594 anti-mouse CD3 17A2 IHC-F, FC, 3D IHC, SB
Brilliant Violet 711™ anti-mouse CD3 17A2 FC
Biotin anti-mouse CD3 17A2 FC, IHC-F
PE/Dazzle™ 594 anti-mouse CD3 17A2 FC
APC/Fire™ 750 anti-mouse CD3 17A2 FC
Brilliant Violet 750™ anti-mouse CD3 17A2 FC
TotalSeq™-A0182 anti-mouse CD3 17A2 PG
TotalSeq™-B0182 anti-mouse CD3 17A2 PG
Spark Blue™ 550 anti-mouse CD3 17A2 FC
Spark NIR™ 685 anti-mouse CD3 17A2 FC
TotalSeq™-C0182 anti-mouse CD3 17A2 PG
APC/Fire™ 810 anti-mouse CD3 17A2 FC
PE/Fire™ 640 anti-mouse CD3 17A2 FC
Spark YG™ 570 anti-mouse CD3 17A2 IHC-F
PE/Fire™ 700 anti-mouse CD3 17A2 FC
PE/Cyanine5 anti-mouse CD3 17A2 FC
Spark Blue™ 574 anti-mouse CD3 Antibody 17A2 FC
Spark Violet™ 423 anti-mouse CD3 17A2 FC
PE/Fire™ 810 anti-mouse CD3 17A2 FC
Spark Red™ 718 anti-mouse CD3 17A2 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • FITC anti-mouse CD3

  • PE anti-mouse CD3

  • Purified anti-mouse CD3

  • Alexa Fluor® 647 anti-mouse CD3

  • Alexa Fluor® 488 anti-mouse CD3

  • Pacific Blue™ anti-mouse CD3

  • Alexa Fluor® 700 anti-mouse CD3

  • PerCP/Cyanine5.5 anti-mouse CD3

  • PE/Cyanine7 anti-mouse CD3

  • APC/Cyanine7 anti-mouse CD3

  • Brilliant Violet 421™ anti-mouse CD3

  • Brilliant Violet 570™ anti-mouse CD3

  • Brilliant Violet 650™ anti-mouse CD3

  • Brilliant Violet 785™ anti-mouse CD3

  • Brilliant Violet 510™ anti-mouse CD3

  • APC anti-mouse CD3

  • Ultra-LEAF™ Purified anti-mouse CD3

  • Brilliant Violet 605™ anti-mouse CD3

  • Alexa Fluor® 594 anti-mouse CD3

  • Brilliant Violet 711™ anti-mouse CD3

  • Biotin anti-mouse CD3

  • PE/Dazzle™ 594 anti-mouse CD3

  • APC/Fire™ 750 anti-mouse CD3

  • Brilliant Violet 750™ anti-mouse CD3

  • TotalSeq™-A0182 anti-mouse CD3

  • TotalSeq™-B0182 anti-mouse CD3

  • Spark Blue™ 550 anti-mouse CD3

  • Spark NIR™ 685 anti-mouse CD3

  • TotalSeq™-C0182 anti-mouse CD3

  • APC/Fire™ 810 anti-mouse CD3

  • PE/Fire™ 640 anti-mouse CD3

  • Spark YG™ 570 anti-mouse CD3

  • PE/Fire™ 700 anti-mouse CD3

  • PE/Cyanine5 anti-mouse CD3

  • Spark Blue™ 574 anti-mouse CD3 Antibody

  • Spark Violet™ 423 anti-mouse CD3

  • PE/Fire™ 810 anti-mouse CD3

  • Spark Red™ 718 anti-mouse CD3

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account